Canadian clinical trial registry

Go to Health Care Provider version

Centres

Study Description

This is a Phase 1 clinical trial designed to study a drug called 23ME-00610 in children and adults with advanced solid tumors that have not responded to or gotten worse after stardard therapy, or where no further standard therapy exists. In Part A of this study, researchers are looking to find the best possible dose of 23ME-00610 (called the recommended phase 2 dose). Part B of this study will evaluate how the patients body responds to the drug 23ME-00610 and continue monitoring safety. 

Inclusion Criteria

• To enroll in Part B of the study, the patient must be  ≥ 12 years of age
• Patient must weigh at least 40kg
• Patient must have a solid tumor:
  • that has progressed after all available standard therapy
  • or for which standard therapy has been ineffective
  • or for which no standard therapy exists
• Patient is up and about for at least half of their waking hours 
• Patient must have a solid tumor that has not previously been exposed to radiation

Additional inclusion or exclusion criteria may apply and will be discussed with you by the study team 

Go to Health Care Provider version

Centres

Study Description

This study will assess the molecular subtype (abbreviated WNT, SHH, Non-WNT, Non-SHH) of patients with medulloblastoma. Based on the subtype And other factors, patients will be assigned to a "risk group", each risk group receiving specific treatment with chemotherapy and radiation therapy.

Patients with a specific molecular subtype called Sonic Hedgehog (SHH) will be treated with a medication taken by mouth, called vismodegib in addition to standard therapy, to directly target the molecular pathway. 

Inclusion Criteria

• Patients between 3 and 22 years of age with medulloblastoma.
• Patients between 22 and 40 years with medulloblastoma of the SHH subtype are eligible.
• Multiple other inclusion and exclusion criteria could apply and will be reviewed by your treating team.

Go to Health Care Provider version

Centres

Study Description

This study seeks to test the safety and effectiveness of the drug taken by mouth called idasanutlin when taken together with chemotherapy or other cancer drugs (venetoclax) to treat acute leukemias or solid tumors in pediatric or young adults. 

The study is divided into 3 parts. The first part of the study aims to figure out the maximum dose of idasanutlin that can be safely tolerated as well as the recommended dose of idasanutlin when used in combination with chemotherapy and other cancer drugs (venetoclax).

The second part of the study aims to test the safety and effectiveness of idasanutlin in combination with chemotherapy and other cancer drugs (venetoclax) for treating neuroblastoma, acute myeloid leukemia (AML), and acute lymphoblastic leukemia (ALL).

The third part of the study further monitors patients for additional responses to idasanutlin and safety assessments.

Inclusion Criteria

• Age less than 18 years old or less than 30 years old depending on study groups
• Diagnosis of neuroblastoma, acute myeloid leukemia (AML), or acute lymphoblastic leukemia (ALL) that has worsened or come back despite the use of standard therapy.
• Multiple other inclusion and exclusion criteria could apply and will be reviewed by your treating team

Go to Health Care Provider version

Centres

Study Description

The purpose of this study is to determine the best dose, benefits and/or side effects of 2 drugs (magrolimab and dinutuximab) when given in combination to treat neuroblastoma that has come back (relapsed) or does not respond to treatment (refractory), or osteosarcoma that has come back (relapsed). These drugs (magrolimab and dinutuximab) interfere with the ability of cancer cells to grow and spread, using them in treatment may stop or shrink cancer growth in cases of neuroblastoma and osteosarcoma.

An additional aim of this study is determining the safety of these drugs (magrolimab and dinutuximab) when given after surgery to remove tumors from the lungs.

Inclusion Criteria

• Age between 1 and 35 years
• Patients must have:
  • neuroblastoma that has come back (relapsed) or does not respond to treatment (refractory) or
  • osteosarcoma that has come back (relapsed)
• Multiple other inclusion and exclusion criteria could apply and will be reviewed by your treating team

Go to Health Care Provider version

Centres

Study Description

This clinical trial studies the side effects and how well larotrectinib (a medication taken by mouth) works in treating patients with

• solid tumors and brain tumours with a specific gene change called a "TRK fusion", previously untreated
• acute leukemia that has come back, and has a specific gene change called a "TRK fusion".

Larotrectinib may stop the growth of cancer cells with TRK fusions by blocking the TRK enzymes needed for cell growth.

Inclusion Criteria

• Age up to 30 years
• Patients must fit into one of the 3 groups
  • Group A: diagnosis of infantile fibrosarcoma with a specific gene change called a "TRK fusion". The patient will have received no prior anti-cancer therapy, including radiotherapy, other than surgical resection (operation to remove the tumour)
  • Group B: diagnosis of any solid tumor including brain tumours (except high grade gliomas), with a specific gene change called a "TRK fusion". The patient will have received no prior anti-cancer therapy, including radiotherapy, other than surgical resection (operation to remove the tumour)
  • Group C: diagnosis of acute leukemia that has come back, and has a specific gene change called a "TRK fusion".
• Multiple other inclusion and exclusion criteria could apply and will be reviewed by your treating team

Go to Health Care Provider version

Centres

Study Description

(via: https://www.mskcc.org/cancer-care/clinical-trials/21-303)

The purpose of this study is to find the highest dose of the investigational drug RP-6306 that can be used in advanced solid tumors containing certain genetic changes and which have come back or continued to grow despite prior treatment. 

RP-6306 blocks the protein PKMY1, which plays a major role in the survival and growth of cancers with the genetic changes being studied in this clinical trial. RP-6306 is taken orally (by mouth).

Inclusion Criteria

(via: https://www.mskcc.org/cancer-care/clinical-trials/21-303)

To be eligible for this study, patients must meet several criteria, including but not limited to the following:

• Patients must have a locally advanced or metastatic solid tumor that has come back or continued to grow despite prior treatment
• Participants’ tumors must contain a mutation in the FBXW7 or PPP2R1A genes or extra copies of the CCNE1 gene
• Patients must be able to walk and do routine activities for more than half of their normal waking hours
• This study is for people age 12 and older

Multiple other inclusion and exclusion criteria could apply and will be reviewed by your treating team.

Go to Health Care Provider version

Centres

Study Description

This is a study of naxitamab, also known as hu3F8, a humanised antibody targeting GD2 in children and adults diagnosed with high-risk neuroblastoma. GD2 is a marker present at the surface of the neuroblastoma cells; therefore the naxitamab can target the neuroblastoma cells and stimulate the immune system to kill them.

Patients with with primary refractory disease (disease that has never improved with previous treatment), or patients that have had a relapse but incomplete response of the disease in bone and/or bone marrow from salvage treatment will be considered for this study.

Granulocyte-macrophage colony stimulating factor (GM-CSF) will be given along naxitamab.

Inclusion Criteria

• Diagnosis of high-risk neuroblastoma with disease in bone and/or bone marrow.
• High-risk neuroblastoma patients with either primary refractory disease or incomplete response to salvage treatment
• Multiple other inclusion and exclusion criteria could apply and will be reviewed by your treating team

Go to Health Care Provider version

Centres

Study Description

This is study of a new medication called isatuximab (antibody against a marker called CD38) in combination with standard chemotherapy for children with acute lymphoblastic leukemia or acute myeloid leukemia that has relapsed or is refractory to treatment. The main objective of this study is to understand the anti-leukemia effect of this medication. 

Inclusion Criteria

• Age between 28 days to less than 18 years of age
• Acute lymphoblastic leukemia or acute myeloid leukemia that has relapsed or is refractory to treatment
• Multiple other inclusion and exclusion criteria could apply and will be reviewed by your treating team